Klinische Monatsblatter fur Augenheilkunde · 2007
[On the relationship between age and prevalence and/or incidence of primary open-angle glaucoma in the "Salzburg-Moorfields Collaborative Glaucoma Study"].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hitzl W, Hornykewycz K, Grabner G, Reitsamer H A
Аннотация
BACKGROUND: It is the aim of this study to describe both the relationship between age and prevalence as well as age and 5-year incidence of primary open angle glaucoma (POAG) for a homogeneous population cohort. The result of the regression model for the prevalence are compared with the models of Tuck-Crick and Quigley-Vitale. In addition, estimations for the number of 5-year incidence cases of POAG are provided for individuals at the age of 40-80 years in Austria for the years in 2001-2006, 2010-2015, 2020-2025 and 2030-2035.
PATIENTS AND METHODS: The "Salzburg Moorfields Collaborative Glaucoma Study" (SMCGS) is embedded in a government-supported glaucoma blindness prevention programme in Salzburg county, Austria, which is designed for a screening and follow-up period of at least 10 years. Each subject receives a complete ophthalmological examination. In total, the findings of 853 subjects are analysed and evaluated applying the guidelines of the European glaucoma society.
RESULTS: The results of the regression analysis for the prevalences are in good agreement with the models of Tuck-Crick and Quigley-Vitale. The best correlation was found for individuals between 40 and 80 years of age. The 5-year incidences increase is statistically significant (p < 0.001) with increasing age: the 5-year incidences of individuals at the age of 40, 50, 60, 70 and 80 years are 0.07 % (95 % confidence interval: 0.005 - 0.9 %), 0.2 % (0.04 - 1.2 %), 0.7 % (0.3 - 1.9 %), 2.3 % (1 - 5.2 %) and 6.9 % (1.7 - 24.0 %), respectively.
CONCLUSION: The age-dependent prevalences in this glaucoma screening program are in good agreement with the regression models of Tuck-Crick and Quigley-Vitale, especially in the age range of 40 - 80 years. The model for the 5-year incidences describes the tight relationship between age and 5-year risk for POAG. We estimate the number of new POAG cases in Austria in 2001-2006, 2010-2015, 2020-2025 and 2030-2035 at the age between 40 and 80 years to reach 49 100, 52 100, 62 000 and 69 600 patients, respectively.
PATIENTS AND METHODS: The "Salzburg Moorfields Collaborative Glaucoma Study" (SMCGS) is embedded in a government-supported glaucoma blindness prevention programme in Salzburg county, Austria, which is designed for a screening and follow-up period of at least 10 years. Each subject receives a complete ophthalmological examination. In total, the findings of 853 subjects are analysed and evaluated applying the guidelines of the European glaucoma society.
RESULTS: The results of the regression analysis for the prevalences are in good agreement with the models of Tuck-Crick and Quigley-Vitale. The best correlation was found for individuals between 40 and 80 years of age. The 5-year incidences increase is statistically significant (p < 0.001) with increasing age: the 5-year incidences of individuals at the age of 40, 50, 60, 70 and 80 years are 0.07 % (95 % confidence interval: 0.005 - 0.9 %), 0.2 % (0.04 - 1.2 %), 0.7 % (0.3 - 1.9 %), 2.3 % (1 - 5.2 %) and 6.9 % (1.7 - 24.0 %), respectively.
CONCLUSION: The age-dependent prevalences in this glaucoma screening program are in good agreement with the regression models of Tuck-Crick and Quigley-Vitale, especially in the age range of 40 - 80 years. The model for the 5-year incidences describes the tight relationship between age and 5-year risk for POAG. We estimate the number of new POAG cases in Austria in 2001-2006, 2010-2015, 2020-2025 and 2030-2035 at the age between 40 and 80 years to reach 49 100, 52 100, 62 000 and 69 600 patients, respectively.